What is Concert Genetics (fka NextGxDX)?
Formerly known as NextGxDX, Concert Genetics operates as a sophisticated software and managed services provider dedicated to the reliable management of genetic testing. The company leverages a proprietary database of the U.S. clinical genetic testing market to offer a comprehensive technology platform. This infrastructure supports the entire lifecycle of genetic testing, including test ordering, resulting, coding, coverage, and payment integrity. By bridging the gap between clinical necessity and administrative complexity, Concert Genetics enables healthcare providers and payers to navigate the precision medicine era with greater accuracy and reduced friction.
How much funding has Concert Genetics (fka NextGxDX) raised?
Concert Genetics (fka NextGxDX) has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Concert Genetics (fka NextGxDX)
PPP
Public-Private Partnership
What's next for Concert Genetics (fka NextGxDX)?
With this recent capital injection, Concert Genetics is well-positioned to scale its digital infrastructure and expand its influence within the clinical diagnostics ecosystem. The company's focus on payment integrity and market-leading expertise suggests a strategic pivot toward deeper integration with large-scale health systems and insurance providers. As the demand for precision medicine continues to accelerate, Concert's ability to provide a unified, data-driven platform will be instrumental in driving industry-wide standardization and operational excellence. Future growth will likely center on enhancing its proprietary database capabilities and broadening its suite of managed services to address the evolving regulatory and financial requirements of the genetic testing market.
See full Concert Genetics (fka NextGxDX) company page
